Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease

Figure 4 Prophylaxis against atypical hemolytic uremic syndrome recurrence in allograft based on a risk-assessment strategy[96] (Adapted from: Goodship et al[58]). ¹Requires complete screening of all genes implicated in atypical hemolytic uremic syndrome; ²Prophylactic regimens are based on local center protocols; no trial data exist to support superiority of one protocol over another; ³Liver transplantation can be considered for renal transplant recipients with liver-derived complement protein abnormalities, uncontrolled disease activity despite eculizumab therapy or financial considerations regarding cost of long-term eculizumab therapy; ⁴Decision to perform or not to perform prophylactic plasma exchange or complement inhibition is left to the discretion of the clinician. aHUS: Atypical hemolytic uremic syndrome; CFI: Complement factor I gene; FH: Complement factor H protein; MCP: Membrane cofactor protein gene.